Previous close | 16.58 |
Open | 16.87 |
Bid | 15.85 x 0 |
Ask | 18.40 x 0 |
Day's range | 16.87 - 17.05 |
52-week range | 8.08 - 17.68 |
Volume | |
Avg. volume | 54,575 |
Market cap | 23.682B |
Beta (5Y monthly) | 1.15 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.